1
|
Venditto NJ, Boerth JA. Deoxy-Arylation of Amides via a Tandem Hydrosilylation/Radical- Radical Coupling Sequence. Org Lett 2024; 26:3617-3621. [PMID: 38651818 DOI: 10.1021/acs.orglett.4c01121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/25/2024]
Abstract
Vaska's complex is a prominent catalyst for the hydrosilylation of amides. The O-silyl hemiaminal intermediate formed in these processes has been demonstrated as an electrophile for nucleophilic additions. More recently, these intermediates have been shown to be suitable for single electron reduction to generate α-amino radicals. Leveraging the ability to generate α-amino radicals from these hemiaminals, we describe a two-step, one-pot, deoxy-arylation of amides utilizing iridium-catalyzed hydrosilylation and photoredox catalysis. This transformation can be tailored toward the late-stage functionalization of biologically relevant molecules, with drug discovery applications as shown in the streamlined synthesis of an NPY Y2 inhibitor.
Collapse
Affiliation(s)
- Nicholas J Venditto
- Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Jeffrey A Boerth
- Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| |
Collapse
|
2
|
Mfuh AM, Boerth JA, Bommakanti G, Chan C, Chinn AJ, Code E, Fricke PJ, Giblin KA, Gohlke A, Hansel C, Hariparsad N, Hughes SJ, Jin M, Kantae V, Kavanagh SL, Lamb ML, Lane J, Moore R, Puri T, Quinn TR, Reddy I, Robb GR, Robbins KJ, Gancedo Rodrigo M, Schimpl M, Singh B, Singh M, Tang H, Thomson C, Walsh JJ, Ware J, Watson IDG, Ye MW, Wrigley GL, Zhang AX, Zhang Y, Grimster NP. Discovery, Optimization, and Biological Evaluation of Arylpyridones as Cbl-b Inhibitors. J Med Chem 2024; 67:1500-1512. [PMID: 38227216 DOI: 10.1021/acs.jmedchem.3c02083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2024]
Abstract
Casitas B-lymphoma proto-oncogene-b (Cbl-b), a member of the Cbl family of RING finger E3 ubiquitin ligases, has been demonstrated to play a central role in regulating effector T-cell function. Multiple studies using gene-targeting approaches have provided direct evidence that Cbl-b negatively regulates T, B, and NK cell activation via a ubiquitin-mediated protein modulation. Thus, inhibition of Cbl-b ligase activity can lead to immune activation and has therapeutic potential in immuno-oncology. Herein, we describe the discovery and optimization of an arylpyridone series as Cbl-b inhibitors by structure-based drug discovery to afford compound 31. This compound binds to Cbl-b with an IC50 value of 30 nM and induces IL-2 production in T-cells with an EC50 value of 230 nM. Compound 31 also shows robust intracellular target engagement demonstrated through inhibition of Cbl-b autoubiquitination, inhibition of ubiquitin transfer to ZAP70, and the cellular modulation of phosphorylation of a downstream signal within the TCR axis.
Collapse
Affiliation(s)
- Adelphe M Mfuh
- Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Jeffrey A Boerth
- Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Gayathri Bommakanti
- Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | | | - Alex J Chinn
- Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Erin Code
- Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Patrick J Fricke
- Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | | | - Andrea Gohlke
- Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K
| | | | - Niresh Hariparsad
- Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | | | - Meizhong Jin
- Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Vasudev Kantae
- Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K
| | | | - Michelle L Lamb
- Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Jordan Lane
- Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K
| | - Rachel Moore
- Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K
| | - Taranee Puri
- Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Taylor R Quinn
- Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Iswarya Reddy
- Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | | | - Kevin J Robbins
- Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Miguel Gancedo Rodrigo
- Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K
- Isomorphic Laboratories, 280 Bishopsgate, London EC2M 4RB, U.K
| | | | - Baljinder Singh
- Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Meha Singh
- Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Haoran Tang
- Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K
| | | | - Jarrod J Walsh
- Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K
| | - Jamie Ware
- Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K
| | - Iain D G Watson
- Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Min-Wei Ye
- Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | | | - Andrew X Zhang
- Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Yun Zhang
- Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Neil P Grimster
- Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| |
Collapse
|
3
|
Boerth JA, Chinn AJ, Schimpl M, Bommakanti G, Chan C, Code EL, Giblin KA, Gohlke A, Hansel CS, Jin M, Kavanagh SL, Lamb ML, Lane JS, Larner CJB, Mfuh AM, Moore RK, Puri T, Quinn TR, Ye M, Robbins KJ, Gancedo-Rodrigo M, Tang H, Walsh J, Ware J, Wrigley GL, Reddy IK, Zhang Y, Grimster NP. Discovery of a Novel Benzodiazepine Series of Cbl-b Inhibitors for the Enhancement of Antitumor Immunity. ACS Med Chem Lett 2023; 14:1848-1856. [PMID: 38116444 PMCID: PMC10726479 DOI: 10.1021/acsmedchemlett.3c00439] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2023] [Revised: 11/09/2023] [Accepted: 11/10/2023] [Indexed: 12/21/2023] Open
Abstract
Casitas B-lineage lymphoma proto-oncogene-b (Cbl-b) is a RING finger E3 ligase that is responsible for repressing T-cell, natural killer (NK) cell, and B-cell activation. The robust antitumor activity observed in Cbl-b deficient mice arising from elevated T-cell and NK-cell activity justified our discovery effort toward Cbl-b inhibitors that might show therapeutic promise in immuno-oncology, where activation of the immune system can drive the recognition and killing of cancer cells. We undertook a high-throughput screening campaign followed by structure-enabled optimization to develop a novel benzodiazepine series of potent Cbl-b inhibitors. This series displayed nanomolar levels of biochemical potency, as well as potent T-cell activation. The functional activity of this class of Cbl-b inhibitors was further corroborated with ubiquitin-based cellular assays.
Collapse
Affiliation(s)
- Jeffrey A. Boerth
- Medicinal
Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Alex J. Chinn
- Medicinal
Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Marianne Schimpl
- Discovery
Sciences, R&D, The Discovery Centre, AstraZeneca, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom
| | - Gayathri Bommakanti
- Bioscience,
Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Christina Chan
- DMPK,
Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom
| | - Erin L. Code
- Discovery
Sciences, R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Kathryn A. Giblin
- Medicinal
Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge
Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom
| | - Andrea Gohlke
- Discovery
Sciences, R&D, The Discovery Centre, AstraZeneca, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom
| | - Catherine S. Hansel
- Discovery
Sciences, R&D, The Discovery Centre, AstraZeneca, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom
| | - Meizhong Jin
- Medicinal
Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Stefan L. Kavanagh
- Clinical
Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom
| | - Michelle L. Lamb
- Medicinal
Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Jordan S. Lane
- Discovery
Sciences, R&D, The Discovery Centre, AstraZeneca, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom
| | - Carrie J. B. Larner
- Clinical
Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom
| | - Adelphe M. Mfuh
- Medicinal
Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Rachel K. Moore
- High
Throughput Screening, Hit Discovery, Discovery Sciences, R&D BioPharmaceuticals, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, United Kingdom
| | - Taranee Puri
- Medicinal
Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Taylor R. Quinn
- Medicinal
Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Minwei Ye
- Bioscience,
Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Kevin J. Robbins
- Medicinal
Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Miguel Gancedo-Rodrigo
- Discovery
Sciences, R&D, The Discovery Centre, AstraZeneca, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom
| | - Haoran Tang
- Discovery
Sciences, R&D, The Discovery Centre, AstraZeneca, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom
| | - Jarrod Walsh
- High
Throughput Screening, Hit Discovery, Discovery Sciences, R&D BioPharmaceuticals, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, United Kingdom
| | - Jamie Ware
- Discovery
Sciences, R&D, The Discovery Centre, AstraZeneca, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom
| | - Gail L. Wrigley
- Medicinal
Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge
Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom
| | - Iswarya Karapa Reddy
- Bioscience,
Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Yun Zhang
- Medicinal
Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Neil P. Grimster
- Medicinal
Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| |
Collapse
|
4
|
Venditto NJ, Boerth JA. Photoredox-Catalyzed Multicomponent Synthesis of Functionalized γ-Amino Butyric Acids via Reductive Radical Polar Crossover. Org Lett 2023; 25:3429-3434. [PMID: 37163325 DOI: 10.1021/acs.orglett.3c00991] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
Multicomponent radical polar crossover (RPC) reactions are useful for leveraging both radical and polar bond-forming steps to rapidly build molecular complexity in a single transformation. However, multicomponent RPC reactions that utilize carbonyl π-bond electrophiles are underrepresented in the literature. Herein, we describe a mild, photoredox-catalyzed decarboxylative multicomponent RPC reaction that couples carboxylic acids, Michael acceptors, and carbonyl electrophiles for the formation of diversely functionalized γ-amino butyric acid derivatives. This transformation also facilitates the synthesis of complex and biologically relevant γ-lactam compounds.
Collapse
Affiliation(s)
- Nicholas J Venditto
- Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Jeffrey A Boerth
- Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| |
Collapse
|
5
|
Rasapalli S, Sammeta VR, Murphy ZF, Huang Y, Boerth JA, Golen JA, Savinov SN. Synthesis of C-Ring-Substituted Vasicinones and Luotonins via Regioselective Aza-Nazarov Cyclization of Quinazolinonyl Enones. Org Lett 2019; 21:9824-9828. [PMID: 31800251 DOI: 10.1021/acs.orglett.9b03586] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
A facile synthesis of C-ring substituted luotonins and vasicinones has been realized via a super-acid-mediated aza-Nazarov cyclization of quinazolinonyl enones. The regioselectivity of the cyclization is highly dependent on proton availability in the reaction medium.
Collapse
Affiliation(s)
- Sivappa Rasapalli
- Department of Chemistry and Biochemistry , University of Massachusetts Dartmouth , 285 Old Westport Rd. , North Dartmouth , Massachusetts 02747 , United States
| | - Vamshikrishna Reddy Sammeta
- Department of Chemistry and Biochemistry , University of Massachusetts Dartmouth , 285 Old Westport Rd. , North Dartmouth , Massachusetts 02747 , United States
| | - Zachary F Murphy
- Department of Chemistry and Biochemistry , University of Massachusetts Dartmouth , 285 Old Westport Rd. , North Dartmouth , Massachusetts 02747 , United States
| | - Yanchang Huang
- Department of Chemistry and Biochemistry , University of Massachusetts Dartmouth , 285 Old Westport Rd. , North Dartmouth , Massachusetts 02747 , United States
| | - Jeffrey A Boerth
- Department of Chemistry and Biochemistry , University of Massachusetts Dartmouth , 285 Old Westport Rd. , North Dartmouth , Massachusetts 02747 , United States
| | - James A Golen
- Department of Chemistry and Biochemistry , University of Massachusetts Dartmouth , 285 Old Westport Rd. , North Dartmouth , Massachusetts 02747 , United States
| | - Sergey N Savinov
- Department of Biochemistry and Molecular Biology , University of Massachusetts Amherst , Amherst , Massachusetts 01003 , United States
| |
Collapse
|
6
|
Boerth JA, Ellman JA. A Convergent Synthesis of Functionalized Alkenyl Halides through Cobalt(III)-Catalyzed Three-Component C-H Bond Addition. Angew Chem Int Ed Engl 2017; 56:9976-9980. [PMID: 28657674 PMCID: PMC5568819 DOI: 10.1002/anie.201705817] [Citation(s) in RCA: 66] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2017] [Indexed: 11/11/2022]
Abstract
A CoIII -catalyzed three-component coupling of C(sp2 )-H bonds, alkynes, and halogenating agents to give alkenyl halides is reported. This transformation proceeds with high regio- and diastereoselectivity, and is effective for a broad range of aryl and alkyl terminal alkynes. Diverse C-H bond partners also exhibit good reactivity for a range of heteroaryl and aryl systems as well as synthetically useful secondary and tertiary amide, urea, and pyrazole directing groups. This multicomponent transformation is also compatible with allenes in place of alkynes to furnish tetrasubstituted alkenyl halides, showcasing the first halo-arylation of allenes.
Collapse
Affiliation(s)
- Jeffrey A Boerth
- Department of Chemistry, Yale University, 225 Prospect St., New Haven, CT, 06520, USA
| | - Jonathan A Ellman
- Department of Chemistry, Yale University, 225 Prospect St., New Haven, CT, 06520, USA
| |
Collapse
|
7
|
Boerth JA, Ellman JA. A Convergent Synthesis of Functionalized Alkenyl Halides through Cobalt(III)‐Catalyzed Three‐Component C−H Bond Addition. Angew Chem Int Ed Engl 2017. [DOI: 10.1002/ange.201705817] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Jeffrey A. Boerth
- Department of ChemistryYale University 225 Prospect St. New Haven CT 06520 USA
| | - Jonathan A. Ellman
- Department of ChemistryYale University 225 Prospect St. New Haven CT 06520 USA
| |
Collapse
|
8
|
Abstract
The transition-metal-catalyzed addition of C-H bonds to carbonyls, imines, and related polarized π bonds has emerged as a particularly efficient and powerful approach for the construction of an incredibly diverse array of heteroatom-substituted products. Readily available and stable inputs are typically employed, and reactions often proceed with very high functional group compatibility and without the production of waste byproducts. Additionally, many transition-metal-catalyzed C-H bond additions to polarized π bonds occur within cascade reaction sequences to provide rapid access to a diverse array of different heterocyclic as well as carbocyclic products. This review highlights the diversity of transformations that have been achieved, catalysts that have been used, and types of products that have been prepared through the transition-metal-catalyzed addition of C-H bonds to carbonyls, imines, and related polarized π bonds.
Collapse
Affiliation(s)
- Joshua R Hummel
- Department of Chemistry, Yale University , 225 Prospect Street, New Haven, Connecticut 06520, United States
| | - Jeffrey A Boerth
- Department of Chemistry, Yale University , 225 Prospect Street, New Haven, Connecticut 06520, United States
| | - Jonathan A Ellman
- Department of Chemistry, Yale University , 225 Prospect Street, New Haven, Connecticut 06520, United States
| |
Collapse
|
9
|
Abstract
A highly stereoselective three-component C(sp(2) )-H bond addition across alkene and polarized π-bonds is reported for which Co(III) catalysis was shown to be much more effective than Rh(III) . The reaction proceeds at ambient temperature with both aryl and alkyl enones employed as efficient coupling partners. Moreover, the reaction exhibits extremely broad scope with respect to the aldehyde input; electron rich and poor aromatic, alkenyl, and branched and unbranched alkyl aldehydes all couple in good yield and with high diastereoselectivity. Multiple directing groups participate in this transformation, including pyrazole, pyridine, and imine functional groups. Both aromatic and alkenyl C(sp(2) )-H bonds undergo the three-component addition cascade, and the alkenyl addition product can readily be converted into diastereomerically pure five-membered lactones. Additionally, the first asymmetric reactions with Co(III) -catalyzed C-H functionalization are demonstrated with three-component C-H bond addition cascades employing N-tert-butanesulfinyl imines. These examples represent the first transition metal catalyzed C-H bond additions to N-tert-butanesulfinyl imines, which are versatile and extensively used intermediates for the asymmetric synthesis of amines.
Collapse
Affiliation(s)
- Jeffrey A Boerth
- Department of Chemistry, Yale University, 225 Prospect St., New Haven, CT, 06520, USA
| | - Joshua R Hummel
- Department of Chemistry, Yale University, 225 Prospect St., New Haven, CT, 06520, USA
| | - Jonathan A Ellman
- Department of Chemistry, Yale University, 225 Prospect St., New Haven, CT, 06520, USA.
| |
Collapse
|
10
|
Affiliation(s)
- Jeffrey A. Boerth
- Department of Chemistry; Yale University; 225 Prospect St. New Haven CT 06520 USA
| | - Joshua R. Hummel
- Department of Chemistry; Yale University; 225 Prospect St. New Haven CT 06520 USA
| | - Jonathan A. Ellman
- Department of Chemistry; Yale University; 225 Prospect St. New Haven CT 06520 USA
| |
Collapse
|
11
|
Boerth JA, Ellman JA. Rh(III)-Catalyzed Diastereoselective C-H Bond Addition/Cyclization Cascade of Enone Tethered Aldehydes. Chem Sci 2016; 7:1474-1479. [PMID: 26918112 PMCID: PMC4762265 DOI: 10.1039/c5sc04138d] [Citation(s) in RCA: 82] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2015] [Accepted: 11/23/2015] [Indexed: 11/21/2022] Open
Abstract
The Rh(III)-catalyzed cascade addition of a C-H bond across alkene and carbonyl π-bonds is reported. The reaction proceeds under mild reaction conditions with low catalyst loading. A range of directing groups were shown to be effective as was the functionalization of alkenyl in addition to aromatic C(sp2)-H bonds. When the enone and aldehyde electrophile were tethered together, cyclic β-hydroxy ketones with three contiguous stereocenters were obtained with high diastereoselectivity. The intermolecular three-component cascade reaction was demonstrated for both aldehyde and imine electrophiles. Moreover, the first x-ray structure of a cationic Cp*Rh(III) enolate with interatomic distances consistent with an η3-bound enolate is reported.
Collapse
Affiliation(s)
- Jeffrey A Boerth
- Department of Chemistry, Yale University, Connecticut, 06520, USA. Tel: +1-203-432-2647
| | - Jonathan A Ellman
- Department of Chemistry, Yale University, Connecticut, 06520, USA. Tel: +1-203-432-2647
| |
Collapse
|
12
|
Duncan B, Li X, Landis RF, Kim ST, Gupta A, Wang LS, Ramanathan R, Tang R, Boerth JA, Rotello VM. Nanoparticle-Stabilized Capsules for the Treatment of Bacterial Biofilms. ACS Nano 2015; 9:7775-82. [PMID: 26083534 PMCID: PMC5047390 DOI: 10.1021/acsnano.5b01696] [Citation(s) in RCA: 93] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/07/2023]
Abstract
Bacterial biofilms are widely associated with persistent infections. High resistance to conventional antibiotics and prevalent virulence makes eliminating these bacterial communities challenging therapeutic targets. We describe here the fabrication of a nanoparticle-stabilized capsule with a multicomponent core for the treatment of biofilms. The peppermint oil and cinnamaldehyde combination that comprises the core of the capsules act as potent antimicrobial agents. An in situ reaction at the oil/water interface between the nanoparticles and cinnamaldehyde structurally augments the capsules to efficiently deliver the essential oil payloads, effectively eradicating biofilms of clinically isolated pathogenic bacteria strains. In contrast to their antimicrobial action, the capsules selectively promoted fibroblast proliferation in a mixed bacteria/mammalian cell system making them promising for wound healing applications.
Collapse
Affiliation(s)
- Bradley Duncan
- Department of Chemistry, University of Massachusetts Amherst, 710 North Pleasant Street, Amherst, MA 01003, USA
| | - Xiaoning Li
- Department of Chemistry, University of Massachusetts Amherst, 710 North Pleasant Street, Amherst, MA 01003, USA
| | - Ryan F. Landis
- Department of Chemistry, University of Massachusetts Amherst, 710 North Pleasant Street, Amherst, MA 01003, USA
| | - Sung Tae Kim
- Department of Chemistry, University of Massachusetts Amherst, 710 North Pleasant Street, Amherst, MA 01003, USA
| | - Akash Gupta
- Department of Chemistry, University of Massachusetts Amherst, 710 North Pleasant Street, Amherst, MA 01003, USA
| | - Li-Sheng Wang
- Department of Chemistry, University of Massachusetts Amherst, 710 North Pleasant Street, Amherst, MA 01003, USA
| | - Rajesh Ramanathan
- Department of Chemistry, University of Massachusetts Amherst, 710 North Pleasant Street, Amherst, MA 01003, USA
- Ian Potter NanoBioSensing Facility and NanoBiotechnology Research Laboratory, School of Applied Sciences, RMIT University, GPO Box 2476 V, Melbourne, VIC 3001, Australia
| | - Rui Tang
- Department of Chemistry, University of Massachusetts Amherst, 710 North Pleasant Street, Amherst, MA 01003, USA
| | - Jeffrey A. Boerth
- Department of Chemistry, University of Massachusetts Amherst, 710 North Pleasant Street, Amherst, MA 01003, USA
| | - Vincent M. Rotello
- Department of Chemistry, University of Massachusetts Amherst, 710 North Pleasant Street, Amherst, MA 01003, USA
| |
Collapse
|